HRX215 drug study for colorectal cancer spread to liver
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called HRX215 in patients with colorectal cancer that has spread to the liver. Patients must be scheduled for a procedure to reduce liver blood flow (portal vein embolization) before surgery to remove the cancer, and the study will see if this drug helps prepare the liver for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–90 years old
- Colorectal cancer that has spread to your liver and is considered removable by surgery
- Scheduled for portal vein embolization (a procedure to reduce blood flow to part of your liver before surgery)
- Recent CT scan of your liver (within 21 days) that shows the cancer
- Good overall health status (able to do light activities, not bedridden)
- Normal or near-normal blood counts, kidney function, and liver function tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called HRX215 to see if it is safe and helps the liver recover after surgery to remove colon cancer tumors that have spread to the liver. It is for people who are having either a minor or major liver resection and have a low risk of liver failure.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This trial tests a combination of two study drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments. It aims to see if the combination can help shrink tumors.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.